Many studies have demonstrated that SIRT1 was overexpressed in prostate, liver, lymphoma, colon, breast and gastric cancers [4,5]; and it is thought that inhibiting its activity could be a potential strategy for cancer treatment. This evidence concerns the gene SIRT1 and cancer.